Navigation Links
New FDA Approved Breast Cancer Screening Tool
Date:12/6/2009

SCOTTSDALE, Ariz., Dec. 6 /PRNewswire/ -- The FDA has approved new technology that now allows radiologists to detect breast cancer sooner and faster. The SonoCine Automated Whole-breast Ultrasound Method and is being offered by only one facility in Arizona - Arizona Breastnet, in Scottsdale. This unique technology is designed specifically as a breast cancer screening tool to enhance yearly mammography screening. Until now, ultrasound has only been used for diagnostic purposes - not for screening for breast cancer.

A new study, published in European Radiology, found that adding the SonoCine automated whole-breast ultrasound exam to the annual mammogram doubled the number of cancers found in a group representing approximately 40% of all women seeking annual mammograms. This contrasts with previous studies which have examined the use of additional tests only on women with significantly elevated risks of developing breast cancer.

Local radiologist, Belinda Barclay-White, MD, is the first physician to offer this technology in Arizona, and has already experienced its powerful capabilities.

According to Dr. Barclay-White, "87% of all breast cancers are found in women who have none of the traditional risk factors, such as family history. There have been many studies done on women with the BRAC1 and BRAC2 breast cancer gene and other risk factors, but not much is being done for relatively normal women for whom the mammogram does not always provide a complete picture."

In women with dense breasts, mammograms are more difficult to interpret because it can be difficult to 'see through' the dense tissue, which appears white on the mammogram. Cancerous lumps also appear white, so they become invisible and difficult to differentiate. The SonoCine Method can detect small cancers because the dense breast tissue appears white while cancerous tissue appears dark. It also takes an ultrasound video of an entire patient's breast exam, instead of just single pictures, so it can be stopped, can be magnified and the radiologist can even go back and forth to be sure nothing is missed.

"It is not a replacement for screening mammography, but an additional exam for women with dense breasts and for some women with breast implants," explains Dr. Barclay-White. "There are relatively few radiologists trained to offer screening ultrasound as part of the breast screening process, even though the advantages are many. It is less expensive than MRI, there are no contrast injections, no radio nuclide injections, no radiation and no breast compression. In experienced hands, we do not have the high false positive biopsy rates we see with MRI. When cancers are found with ultrasound, they are significantly smaller than when they are eventually visible on mammograms, making treatment outcomes very positive."

Since acquiring SonoCine, Breastnet has found two breast cancers. One was not visible on the mammogram or on a recent MRI and was not present on an ultrasound 15 months prior. Barclay-White performed a screening SonoCine UltraSound on the patient and found a 5mm invasive non-palpable ductal carcinoma. "Early detection really does save lives and to find this type of cancer at such a small size is significant when we are talking about patient outcomes," according to Barclay-White.

Patients at Arizona Breastnet, who are candidates for SonoCine UltraSound, are happily adding this screening tool to their yearly mammogram program for added peace of mind, even though it is not covered by insurance. All women should be made aware that it is now available and should check to see if they are candidates for the exam. The cost is $300.

About Breastnet:

Arizona Breastnet LLC. was founded in 1998 by Dr. Belinda Barclay-White, who has been practicing radiology in Phoenix since 1983. Breastnet specializes in medical conditions related to the breast. Dr. Barclay-White has gained a reputation as an expert mammographer among general surgeons, breast surgeons, gynecologists and primary care physicians, and has acquired a following of patients in the Valley for whom she has diagnosed breast cancer and other various breast conditions. Patients meet with her at the time of the appointment and she reviews the exam with them so they no longer have to worry, wonder and wait for results.

About SonoCine:

SonoCine automated whole breast ultrasound is a computer-guided scanning system that uses sound waves to image different tissue structures. It is the same technology expectant mothers use to see their unborn babies and involves no radiation or injections. There are a limited number of systems being offered to physicians in the US and SonoCine asked Dr. Barclay-White to be one of the first centers of excellence because of her reputation as an expert in the detection of breast cancer.

Arizona Breastnet, 8994 E. Desert Cove Ave, Scottsdale, AZ, 85260. More information can be found at www.AZBreastnet.com

SOURCE Arizona Breastnet LLC


'/>"/>
SOURCE Arizona Breastnet LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)...  Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" ... of its issued and outstanding shares of common stock ... 11, 2016. The Company,s common stock will trade on ... temporary ticker symbol "RCHAD". After 20 trading days, the ... (RCHA).  --> --> ...
(Date:2/10/2016)... , Feb. 10, 2016  The Baylor ... received an in-kind gift from ... VeinViewer® Vision vein finder for the nursing ... students as they learn how to start ... with traditional technique. ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... practitioner, is known locally for a series of therapeutic sessions to help Los ... their characters and in their lives. The series, known as “Mindfulness for Actors ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop ... revolutionary new 2.0 version at the International Roofing Expo in Orlando, Florida on ... the world's most advanced weather technology in the hands of consumers, roofing contractors, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency in Garland, ... the local community. Pledging to select a new beneficiary every 60 days, the ... Their goal is to bring community awareness to important local causes by forming ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
(Date:2/10/2016)... ... 10, 2016 , ... Armune BioScience signed a definitive agreement with ... service centers across the country. Launched in April of 2015, Apifiny is the only ... cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists ...
Breaking Medicine News(10 mins):